COVID-19 in lung transplant recipients—Risk prediction and outcomes

• DOI: 10.1371/journal.pone.0257807
• Publication Date: 2021-10-06T20:51:32Z
• Authors: Jan C. Kamp; Jan B. Hinrichs; Jan Fuge; Raphael Ewen; Jens Gottlieb
• Keywords: Adult; Male; Science; Q; R; COVID-19; Middle Aged; Risk Assessment; Transplant Recipients; 3. Good health; Hospitalization; 03 medical and health sciences; 0302 clinical medicine; Quality of Life; Medicine; Humans; Female; Research Article; Lung Transplantation; Retrospective Studies

Patients after lung transplantation are at risk for life-threatening infections. Recently, several publications on COVID-19 outcomes in this patient population appeared, but knowledge on optimal treatment, mortality, outcomes, and appropriate risk predictors is limited. A retrospective analysis was performed in a German high-volume lung transplant center between 19th March 2020 and 18th May 2021. Impact of COVID-19 on physical and psychological health, clinical outcomes, and mortality were analyzed including follow-up visits up to 12 weeks after infection in survivors. Predictive parameters on survival were assessed using univariate and multivariate proportional hazards regression models. Out of 1,046 patients in follow-up, 31 acquired COVID-19 during the pandemic. 12 of 31 (39%) died and 26 (84%) were hospitalized. In survivors a significant decline in exercise capacity (p = 0.034), TLC (p = 0.02), and DLCO (p = 0.007) was observed at follow-up after 3 months. Anxiety, depression, and self-assessed quality of life remained stable. Charlson comorbidity index predicted mortality (HR 1.5, 1.1–2.2; p = 0.023). In recipients with pre-existing CLAD, mortality and clinical outcomes were inferior. However, pre-existing CLAD did not predict mortality. COVID-19 remains a life-threatening disease for lung transplant recipients, particularly in case comorbidities. Further studies on long term outcomes and impact on pre-existing CLAD are needed.